

# Dirk Heckl

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10421907/publications.pdf>

Version: 2024-02-01

60  
papers

8,792  
citations

257450

24  
h-index

189892

50  
g-index

64  
all docs

64  
docs citations

64  
times ranked

18943  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells. <i>Science</i> , 2014, 343, 84-87.	12.6	4,210
2	Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells. <i>Science</i> , 2014, 343, 301-305.	12.6	1,371
3	Single-cell RNA-seq reveals changes in cell cycle and differentiation programs upon aging of hematopoietic stem cells. <i>Genome Research</i> , 2015, 25, 1860-1872.	5.5	614
4	Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing. <i>Nature Biotechnology</i> , 2014, 32, 941-946.	17.5	477
5	Refined sgRNA efficacy prediction improves large- and small-scale CRISPR-Cas9 applications. <i>Nucleic Acids Research</i> , 2018, 46, 1375-1385.	14.5	213
6	Core Circadian Clock Genes Regulate Leukemia Stem Cells in AML. <i>Cell</i> , 2016, 165, 303-316.	28.9	200
7	Gli1 + Mesenchymal Stromal Cells Are a Key Driver of Bone Marrow Fibrosis and an Important Cellular Therapeutic Target. <i>Cell Stem Cell</i> , 2017, 20, 785-800.e8.	11.1	195
8	Role of Casein Kinase 1A1 in the Biology and Targeted Therapy of del(5q) MDS. <i>Cancer Cell</i> , 2014, 26, 509-520.	16.8	158
9	Pharmacological GLI2 inhibition prevents myofibroblast cell-cycle progression and reduces kidney fibrosis. <i>Journal of Clinical Investigation</i> , 2015, 125, 2935-2951.	8.2	143
10	Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon- $\gamma$ in a murine model of polycythemia vera. <i>Blood</i> , 2013, 121, 3692-3702.	1.4	140
11	The non-coding RNA landscape of human hematopoiesis and leukemia. <i>Nature Communications</i> , 2017, 8, 218.	12.8	131
12	Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome. <i>Cancer Cell</i> , 2019, 36, 123-138.e10.	16.8	93
13	Endogenous Tumor Suppressor microRNA-193b: Therapeutic and Prognostic Value in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2018, 36, 1007-1016.	1.6	67
14	Copy-number and gene dependency analysis reveals partial copy loss of wild-type SF3B1 as a novel cancer vulnerability. <i>ELife</i> , 2017, 6, .	6.0	66
15	Efficient generation of gene-modified human natural killer cells via alpharetroviral vectors. <i>Journal of Molecular Medicine</i> , 2016, 94, 83-93.	3.9	65
16	CRISPR-Cas9-induced t(11;19)/MLL-ENL translocations initiate leukemia in human hematopoietic progenitor cells <i>in vivo</i> . <i>Haematologica</i> , 2017, 102, 1558-1566.	3.5	60
17	LncRNA-SLC16A1-AS1 induces metabolic reprogramming during Bladder Cancer progression as target and co-activator of E2F1. <i>Theranostics</i> , 2020, 10, 9620-9643.	10.0	58
18	Jak2V617F and Dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammation. <i>Blood</i> , 2018, 132, 2707-2721.	1.4	56

#	ARTICLE	IF	CITATIONS
19	Lentiviral Vector Induced Insertional Haploinsufficiency of Ebf1 Causes Murine Leukemia. <i>Molecular Therapy</i> , 2012, 20, 1187-1195.	8.2	54
20	RNA-Binding Proteins in Acute Leukemias. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3409.	4.1	36
21	Transient Retrovirus-Based CRISPR/Cas9 All-in-One Particles for Efficient, Targeted Gene Knockout. <i>Molecular Therapy - Nucleic Acids</i> , 2018, 13, 256-274.	5.1	34
22	Gene Therapy of Mpl Deficiency: Challenging Balance Between Leukemia and Pancytopenia. <i>Molecular Therapy</i> , 2010, 18, 343-352.	8.2	27
23	Lentiviral gene transfer regenerates hematopoietic stem cells in a mouse model for Mpl-deficient aplastic anemia. <i>Blood</i> , 2011, 117, 3737-3747.	1.4	27
24	Scavenger receptor class B member 1 ( SCARB1 ) variants modulate hepatitis C virus replication cycle and viral load. <i>Journal of Hepatology</i> , 2017, 67, 237-245.	3.7	26
25	The Regulatory Roles of Long Noncoding RNAs in Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2019, 9, 570.	2.8	26
26	An optimized lentiviral vector system for conditional RNAi and efficient cloning of microRNA embedded short hairpin RNA libraries. <i>Biomaterials</i> , 2017, 139, 102-115.	11.4	24
27	The stem cell-specific long noncoding RNA HOXA10-AS in the pathogenesis of KMT2A-rearranged leukemia. <i>Blood Advances</i> , 2019, 3, 4252-4263.	5.2	22
28	Molecular Mechanisms of the Genetic Predisposition to Acute Megakaryoblastic Leukemia in Infants With Down Syndrome. <i>Frontiers in Oncology</i> , 2021, 11, 636633.	2.8	22
29	The megakaryocytic transcription factor ARID3A suppresses leukemia pathogenesis. <i>Blood</i> , 2022, 139, 651-665.	1.4	20
30	Gene correction of HAX1 reversed Kostmann disease phenotype in patient-specific induced pluripotent stem cells. <i>Blood Advances</i> , 2017, 1, 903-914.	5.2	18
31	Functional characterization of BRCC3 mutations in acute myeloid leukemia with t(8;21)(q22;q22.1). <i>Leukemia</i> , 2020, 34, 404-415.	7.2	16
32	<i>GATA1</i> exerts developmental stage-specific effects in human hematopoiesis. <i>Haematologica</i> , 2018, 103, e336-e340.	3.5	15
33	Alpharetroviral self-inactivating vectors produced by a superinfection-resistant stable packaging cell line allow genetic modification of primary human T lymphocytes. <i>Biomaterials</i> , 2016, 97, 97-109.	11.4	13
34	Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemia. <i>Leukemia</i> , 2020, 34, 2951-2963.	7.2	13
35	Toward Whole-Transcriptome Editing with CRISPR-Cas9. <i>Molecular Cell</i> , 2015, 58, 560-562.	9.7	11
36	Multiple genetically engineered humanized microenvironments in a single mouse. <i>Biomaterials Research</i> , 2016, 20, 19.	6.9	11

#	ARTICLE	IF	CITATIONS
37	Ectopic expression of HOXC6 blocks myeloid differentiation and predisposes to malignant transformation. <i>Experimental Hematology</i> , 2014, 42, 114-125.e4.	0.4	10
38	Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myeloma. <i>Blood Advances</i> , 2021, 5, 2391-2402.	5.2	10
39	Meningioma 1 is indispensable for mixed lineage leukemia-rearranged acute myeloid leukemia. <i>Haematologica</i> , 2020, 105, 1294-1305.	3.5	8
40	Genetic barcoding systematically compares genes in del(5q) MDS and reveals a central role for <i>CSNK1A1</i> in clonal expansion. <i>Blood Advances</i> , 2022, 6, 1780-1796.	5.2	7
41	Chromosome 21 gain is dispensable for transient myeloproliferative disorder driven by a novel GATA1 mutation. <i>Leukemia</i> , 2020, 34, 2503-2508.	7.2	4
42	Pooled Generation of Lentiviral Tetracycline-Regulated microRNA Embedded Short Hairpin RNA Libraries. <i>Human Gene Therapy Methods</i> , 2018, 29, 16-29.	2.1	3
43	MiR-193a Is a Negative Regulator of Hematopoietic Stem Cells and Promotes Anti-Leukemic Effects in Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 2627-2627.	1.4	3
44	Combining LSD1 and JAK-STAT inhibition targets Down syndrome-associated myeloid leukemia at its core. <i>Leukemia</i> , 2022, 36, 1926-1930.	7.2	3
45	Long noncoding RNAs as regulators of pediatric acute myeloid leukemia. <i>Molecular and Cellular Pediatrics</i> , 2022, 9, .	1.8	3
46	Crispr-Cas9 Induced MLL-Rearrangements Cause Clonal Outgrowth in CD34+ Hematopoietic Stem Cells. <i>Blood</i> , 2015, 126, 165-165.	1.4	2
47	Inhibition of the CRBN-DDB1-CUL4-ROC1 E3 Ubiquitin Ligase Mediates the Anti-Proliferative and Immunomodulatory Properties of Lenalidomide. <i>Blood</i> , 2012, 120, 919-919.	1.4	1
48	Lenalidomide Promotes CRBN-Mediated Ubiquitination and Degradation of IKZF1 and IKZF3. <i>Blood</i> , 2013, 122, LBA-5-LBA-5.	1.4	1
49	Crispr-Cas9 Mediated Disruption of Dnmt3a in JakV617F Hematopoietic Stem Cells Accelerates Disease Phenotype and Induces Lethal Myelofibrosis. <i>Blood</i> , 2016, 128, 794-794.	1.4	1
50	The miRNA-193 Family Is a Potent Tumor-Suppressor and a Biomarker for Poor Prognosis in Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 1534-1534.	1.4	1
51	Modelling the Progression of a Preleukemic Stage to Overt Leukemia in Children with Down Syndrome. <i>Blood</i> , 2018, 132, 543-543.	1.4	1
52	Lentiviral Vector Induced Insertional Haploinsufficiency of Ebf1 Causes Leukemia in a Murine Bone Marrow Transplantation Model. <i>Blood</i> , 2011, 118, 671-671.	1.4	0
53	Retroviral Ectopic Expression of a Signaling-Defective Thrombopoietin Receptor (Mpl) Induces a Systemic Loss of Hematopoietic Stem Cells in Mice. <i>Blood</i> , 2011, 118, 4175-4175.	1.4	0
54	Depletion of Jak2V617F MPN Stem Cells by IFN $\gamma$ in a Murine Model of Polycythemia Vera. <i>Blood</i> , 2012, 120, 806-806.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Critical Role Of Casein Kinase (Ck)1± Heterozygote Gene Inactivation In The Clonal Advantage Of Hematopoietic Stem Cells In Del(5q) MDS. Blood, 2013, 122, 98-98.	1.4	0
56	GATA1-Centered Genetic Network on Chromosome 21 Drives Down Syndrome Acute Megakaryoblastic Leukemia. Blood, 2014, 124, 4310-4310.	1.4	0
57	The Mir-193 Family Antagonizes Stem Cell Pathways and Is a Potent Tumor Suppressor in Childhood and Adult Acute Myeloid Leukemia. Blood, 2015, 126, 1244-1244.	1.4	0
58	Deconstructing the Clonal Advantage and Clonal Stability of 5q- Candidate Genes in Del(5q) MDS on a Single Cell Level. Blood, 2019, 134, 559-559.	1.4	0
59	Exome Sequencing of Relapsed Multiple Myeloma Combined with Pooled CRISPR/Cas9 Screens Identifies Gene Mutations Associated with Drug-Specific Resistance. Blood, 2019, 134, 809-809.	1.4	0
60	Characterization of a Novel JAK1 Pseudokinase Mutation in the First Case of Trisomy 21-Independent GATA1-Mutated Transient Abnormal Myelopoiesis. Blood, 2019, 134, 4208-4208.	1.4	0